- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00524186
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib when given together with irinotecan, fluorouracil, and leucovorin in treating patients with advanced stomach cancer or gastroesophageal cancer.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy comprising irinotecan hydrochloride, fluorouracil, and leucovorin calcium in patients with advanced gastroesophageal cancer.
Secondary
- Determine the response rates, overall survival, and progression-free survival of patients treated with this regimen.
- Determine if there is a change in circulating endothelial precursor cell number and VEGF expression as a result of this therapy and if these changes correlate with improved response and survival.
- Document any pharmacokinetic interactions between irinotecan hydrochloride and sunitinib malate.
- Study pharmacokinetics of sunitinib malate on day 14 (steady state) and day 42 (after 6 weeks of continuous dosing).
OUTLINE: Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV over 2 hours beginning on days 1 and 15. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
Blood is collected at baseline and periodically during study for pharmacokinetic and biomarker correlative studies. Samples are analyzed by flow cytometry to assess circulating endothelial cells and VEGF expression.
After completion of study treatment, patients are followed for 4 weeks.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263-0001
- Roswell Park Cancer Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically confirmed diagnosis of 1 of the following:
- Locally advanced or unresectable gastric cancer
- Metastatic gastric adenocarcinoma
Metastatic gastroesophageal junction (GEJ) adenocarcinoma
- Esophageal adenocarcinomas with involvement of GEJ allowed
Exclusion criteria:
- Symptomatic, uncontrolled CNS metastases
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-1
- Life expectancy > 12 weeks
- WBC ≥ 3,000/μL
- Platelet count ≥ 100,000/μL
- Creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Exclusion criteria:
- Uncontrolled infection
- Uncontrolled serious medical disease
- Uncontrolled hypertension
- Coagulopathy or bleeding disorder
- History of allergic reactions attributed to compounds of similar chemical or biological composition to sunitinib malate or other agents used in study
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- No prior chemotherapy for metastatic disease
- Concurrent therapeutic anticoagulation allowed
Exclusion criteria:
- Other concurrent investigational therapy
- Concurrent combination antiretroviral therapy in HIV-positive patients
- Major surgery or radiotherapy within the past 3 weeks
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Oral Sunitinib
Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
|
Givet IV
Givet IV
Givet IV
Korrelativ undersøgelse
Korrelativ undersøgelse
Taken Orally
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)
Tidsramme: 30 days after treatment
|
30 days after treatment
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Samlet overlevelse
Tidsramme: op til 5 år
|
op til 5 år
|
Toxicity
Tidsramme: 28 days
|
28 days
|
Response rate as assessed by RECIST criteria
Tidsramme: Every 3 months up to 5 years
|
Every 3 months up to 5 years
|
Progression-free survival
Tidsramme: Every 3 months up to 5 years
|
Every 3 months up to 5 years
|
Circulating endothelial precursor cell (CEC) number
Tidsramme: At baseline
|
At baseline
|
VEGF expression
Tidsramme: At Baseline
|
At Baseline
|
Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival
Tidsramme: Every 3 months
|
Every 3 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Patrick Boland, MD, Roswell Park Cancer Institute
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Neoplasmer i hoved og hals
- Esophageale sygdomme
- Neoplasmer i maven
- Esophageale neoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Beskyttelsesagenter
- Topoisomerasehæmmere
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Mikronæringsstoffer
- Proteinkinasehæmmere
- Vitaminer
- Calciumregulerende hormoner og midler
- Topoisomerase I-hæmmere
- Modgift
- Vitamin B kompleks
- Fluorouracil
- Sunitinib
- Leucovorin
- Irinotecan
- Kalk
- Levoleucovorin
Andre undersøgelses-id-numre
- CDR0000562762
- RPCI-I-69605
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mavekræft
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertikal ærmegatrektomi | Mavebånd | Bypass, GastricForenede Stater
-
Medtronic - MITGAfsluttet
-
DuomedAktiv, ikke rekrutterendeFedme | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgien
-
Olympus Corporation of the AmericasUnity Health TorontoAfsluttet
-
North Dakota State UniversityNational Institutes of Health (NIH)AfsluttetRoux en Y Gastric Bypass OperationForenede Stater
-
Wageningen UniversityRijnstate HospitalUkendtRoux-en-Y Gastric BypassHolland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAfsluttetRoux en Y Gastric BypassForenede Stater
-
Rijnstate HospitalAfsluttetRoux-en-Y Gastric Bypass | Mavetømning | Bariatrisk kirurgiHolland
-
Rijnstate HospitalAfsluttet
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAfsluttetSleeve Gastrectomy | Roux en Y Gastric BypassForenede Stater
Kliniske forsøg med leucovorin calcium
-
University of California, San FranciscoNational Cancer Institute (NCI)AfsluttetHoved- og halskræftForenede Stater
-
Southwest Autism Research & Resource CenterUnited States Department of Defense; State University of New York - Downstate...RekrutteringAutismespektrumforstyrrelse | SprogforstyrrelserForenede Stater
-
Southwest Autism Research & Resource CenterAutism Speaks; State University of New York - Downstate Medical CenterRekrutteringAutismespektrumforstyrrelse | SprogforstyrrelserForenede Stater
-
University of California, San FranciscoAfsluttet
-
Iwate Medical UniversityUkendt
-
Fudan UniversityRekrutteringLokalt avanceret tyktarmskræftKina
-
AlizymeAfsluttetFedme | Ikke-insulinafhængig diabetes mellitusFinland, Holland, Danmark, Det Forenede Kongerige, Sverige
-
The Hospital for Sick ChildrenUniversity of Florida; Centers for Disease Control and PreventionAfsluttet
-
Hospices Civils de LyonAfsluttetAntibiotisk reaktion | Knogle- og ledinfektionFrankrig
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UkendtAvanceret solid tumorKina